A 38-year-old man is admitted to the hospital with a 1-week history of severe fatigue, eas… — USMLE Step 3

A 38-year-old man is admitted to the hospital with a 1-week history of severe fatigue, easy bruising, and gingival bleeding. Laboratory evaluation reveals a leukocyte count of $3,500/\text{mm}^3$ , hemoglobin of $8.2\text{ g/dL}$ , and platelet count of $22,000/\text{mm}^3$ . Coagulation studies demonstrate a prothrombin time of 18 seconds, activated partial thromboplastin time of 45 seconds, and a fibrinogen level of $90\text{ mg/dL}$ . Bone marrow aspiration and cytogenetics confirm the presence of a $t(15;17)$ translocation. The patient is diagnosed with low-risk acute promyelocytic leukemia and is scheduled to begin induction therapy with all-trans retinoic acid and arsenic trioxide. A baseline electrocardiogram shows a QTc interval of $415\text{ ms}$ . Which of the following are REQUIRED components of the monitoring and treatment evaluation protocol for this patient's new pharmacotherapy? (Select all that apply)

Monitor daily weight, oxygen saturation, and chest radiographs to evaluate for differentiation syndromeCevap
Perform serial electrocardiograms and maintain serum potassium above $4.0\text{ mEq/L}$ and magnesium above $2.0\text{ mEq/L}$ Cevap
C
Initiate prophylactic continuous unfractionated heparin infusion to manage consumptive coagulopathy
D
Discontinue induction therapy immediately if the leukocyte count rises above $20,000/\text{mm}^3$ during the first two weeks
E
Perform serial echocardiography every three weeks to monitor for therapy-induced left ventricular dysfunction

Cevap

The correct required components are monitoring daily weight, oxygen saturation, and chest radiographs to evaluate for differentiation syndrome, alongside performing serial electrocardiograms and maintaining strict electrolyte parameters (potassium > 4.0 mEq/L, magnesium > 2.0 mEq/L).

Induction therapy for low-risk acute promyelocytic leukemia with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is associated with two life-threatening, drug-specific toxicities that require strict monitoring protocols. First, ATRA induces rapid terminal differentiation of malignant promyelocytes, which can trigger differentiation syndrome. This condition is characterized by capillary leak, pulmonary infiltrates, weight gain, and hypoxia; therefore, monitoring daily weight, respiratory parameters, and chest radiographs is critical. Second, ATO significantly prolongs the QTc interval, predisposing patients to Torsades de Pointes. Standard clinical guidelines mandate serial electrocardiograms during induction and the strict maintenance of serum potassium above

4.0\text{ mEq/L}

and magnesium above

2.0\text{ mEq/L}

to minimize arrhythmic risk.

Adım Adım Çözüm

Analyze the clinical scenario

The patient has low-risk acute promyelocytic leukemia (APL) and is starting an anthracycline-free induction regimen with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).

Identifying the specific pharmacological agents is required to anticipate their unique toxicities.

Identify the toxicity profile and monitoring requirements of ATRA

ATRA induces rapid differentiation of malignant promyelocytes, which can trigger a systemic inflammatory response known as differentiation syndrome. This necessitates strict clinical monitoring of respiratory status, fluid balance, and chest imaging.

Differentiation syndrome is a potentially fatal complication presenting with capillary leak, pulmonary infiltrates, and weight gain.

Identify the toxicity profile and monitoring requirements of ATO

ATO significantly prolongs the QTc interval. The standard protocol mandates serial electrocardiograms and strict maintenance of serum potassium (> 4.0 mEq/L) and magnesium (> 2.0 mEq/L).

QTc prolongation predisposes the patient to life-threatening ventricular arrhythmias, specifically Torsades de Pointes.

Evaluate and rule out the incorrect monitoring or treatment strategies

Recognize that APL coagulopathy is driven by hyperfibrinolysis (contraindicating heparin), that ATRA-induced leukocytosis is an expected effect managed with cytoreduction (not discontinuation), and that ATRA/ATO regimens lack the cumulative cardiotoxicity of anthracyclines (making routine serial echocardiography unnecessary).

Distinguishing appropriate disease-specific and drug-specific management from general oncology protocols prevents iatrogenic harm.

Anahtar Kavram

Monitoring and Treatment Evaluation of Acute Promyelocytic Leukemia (APL) Induction Therapy

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru